Foghorn therapeutics to present new preclinical data for brg1/brm inhibitor fhd-286 in combination with anti-pd-1 antibody at society for immunotherapy of cancer 37th annual meeting

Cambridge, mass., nov. 09, 2022 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced new preclinical data for its fhd-286 program will be highlighted in a poster presentation at the society for immunotherapy of cancer's (sitc) 37th annual meeting. the meeting will be held november 8–12, 2022, at the boston convention and exhibition center and virtually.
FHTX Ratings Summary
FHTX Quant Ranking